Astragaloside IV protects against the pathological cardiac hypertrophy in mice

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Molecular Medicine

Background:

• Pathologic cardiac hypertrophy can lead to heart failure, arrhythmia, and sudden death.
• Exploring molecular mechanisms and effective treatments for cardiac hypertrophy is crucial.
• Astragaloside IV (AST-IV), from Astragalus membranaceus, exhibits anti-cancer, anti-oxidative, and anti-inflammatory properties.

Purpose of the Study:

• To investigate the effects of AST-IV on cardiac hypertrophy induced by aortic banding (AB) in mice.
• To elucidate the underlying signaling pathways modulated by AST-IV in cardiac hypertrophy.

Main Methods:

• Cardiac hypertrophy was induced in mice via aortic banding (AB) surgery.
• Mice were treated with AST-IV to assess its therapeutic potential.
• Key signaling pathways, including TBK1/PI3K/AKT and the suppressor of IKKε (SIKE) pathway, were analyzed.

Main Results:

• AST-IV treatment attenuated cardiac hypertrophy, collagen accumulation, and improved cardiac function in AB-induced mice.
• AST-IV administration reduced apoptosis and inflammation in cardiac tissues.
• AST-IV was found to enhance SIKE expression, leading to the inactivation of the TBK1/PI3K/AKT signaling pathway.

Conclusions:

• AST-IV demonstrates a protective effect against pathological cardiac hypertrophy.
• Elevating SIKE expression and suppressing the TBK1/PI3K/AKT pathway are key mechanisms for AST-IV's action.
• AST-IV represents a potential therapeutic candidate for preventing cardiac hypertrophy.